CivicaScript, a Utah-based nonprofit company focused on bringing lower-cost generic medicines to US consumers, announced on Tuesday the appointment of Brent J Eberle, RPh, MBA as its new president, effective 30 September.
Eberle currently serves as chief pharmacy officer at Navitus Health Solutions.
Additionally, Eberle has played a significant role in shaping drug policy at both the state and national levels. He testified before the US House of Representatives Energy and Commerce Subcommittee on Health, sharing his expertise on drug pricing, and served on the Wisconsin Governor's Task Force on Reducing Prescription Drug Prices, a bipartisan group focused on addressing the high cost of prescription medications.
Eberle is to replace CivicaScript's first president, Gina Guinasso, JD, who left in June.
Ned McCoy, Civica president and chief executive officer, said: "We are thrilled to have a business and pharmacy executive of Brent's calibre on board to lead CivicaScript on its important next stage of growth. Given CivicaScript's strong member relationship with Navitus, Brent knows the business and embodies the mission – an ideal foundation to hit the ground running."
Par Health launches generic version of Janumet XR tablets in US
EQL Pharma gains approval to sell Mellozzan in Kazakhstan
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval
DifGen and Apotex report FDA approval of generic Nintedanib Soft Gel Capsules